Literature DB >> 1860646

Interferon-induced chronic active hepatitis?

M O Silva1, K R Reddy, L J Jeffers, M Hill, E R Schiff.   

Abstract

A 54-year-old man with chronic B hepatitis was treated with interferon alfa. Despite resolution of the hepatitis B viral infection, he experienced severe jaundice, ascites, and encephalopathy. Further work-up showed hyperglobulinemia, chiefly immunoglobulin G, and positive smooth muscle and anti-nuclear antibodies. Because of these "autoimmune" features, the patient was treated with prednisone. One month later, a significant clinical and biochemical improvement was observed. A possible autoimmune mechanism induced by interferon alfa is proposed as the cause for the perpetuation of the necroinflammatory activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860646     DOI: 10.1016/0016-5085(91)90547-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

1.  Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B.

Authors:  J Cianciara; T Laskus
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

2.  Risk of autoimmune complications associated with interferon therapy.

Authors:  Marcelo O Silva
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-08

3.  Development of granulomatous hepatitis during treatment with interferon-alpha 2b.

Authors:  A Propst; T Propst; O Dietze; H Kathrein; G Judmeier; W Vogel
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

4.  Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C.

Authors:  A Matsumoto; E Tanaka; T Suzuki; H Ogata; K Kiyosawa
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

Review 5.  Drug-induced "allergic hepatitis".

Authors:  P Podevin; M Biour
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 6.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 7.  Concurrent emergence of hepatitis B e antigen-negative hepatitis B virus variant and autoimmune hepatitis cured by adenine arabinoside monophosphate.

Authors:  H Bécheur; D Valla; M A Loriot; A Attar; F Bloch; J P Petite
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

Review 8.  Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis.

Authors:  M Haria; P Benfield
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

9.  High dose interferon treatment in chronic hepatitis C.

Authors:  S Iino
Journal:  Gut       Date:  1993       Impact factor: 23.059

10.  Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection.

Authors:  G V Gregorio; P Pensati; R Iorio; A Vegnente; G Mieli-Vergani; D Vergani
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.